{
    "nctId": "NCT03742986",
    "briefTitle": "Trial of Nivolumab With Chemotherapy as Neoadjuvant Treatment in Inflammatory Breast Cancer (IBC)",
    "officialTitle": "Phase II Trial of Nivolumab With Chemotherapy as Neoadjuvant Treatment in Inflammatory Breast Cancer (IBC)",
    "overallStatus": "COMPLETED",
    "conditions": "Breast Cancer",
    "studyType": "INTERVENTIONAL",
    "phase": "PHASE2",
    "allocation": "NON_RANDOMIZED",
    "primaryPurpose": "TREATMENT",
    "enrollmentCount": 8,
    "primaryOutcomeMeasure": "Number of Participants Who Had a Pathological Complete Response (pCR)",
    "eligibilityCriteria": "Inclusion Criteria:\n\n* Newly diagnosed inflammatory breast cancer without distant metastases and have not received prior chemotherapy or immunotherapy. All breast cancer subtypes are allowed: Triple negative breast cancer (TNBC); Hormone receptor (HR)-positive and human epidermal growth factor receptor 2 (HER2)-negative; HR-positive or HR-negative and HER2-positive\n\nExclusion Criteria:\n\n* Clinical or radiologic evidence of distant metastases\n* Malignancy that progressed within the last five years.\n* Cardiac disease (history of and/or active disease)\n* HIV positive\n* Neuropathy \u2265 Grade 2, per the NCI CTCAE v5.0\n* Allogeneic stem cell or solid organ transplantation\n* Autoimmune disease where in the opinion of the Investigator would preclude the use of immunotherapy\n* Idiopathic pulmonary fibrosis, organizing pneumonia (e.g., bronchiolitis obliterans), or evidence of active pneumonitis\n* Tuberculosis\n* Pregnancy or lactation\n* Treatment with CD137 agonists or immune checkpoint-blockade therapies, including anti-CD40, anti-CTLA-4, anti-PD-1, and anti-PD-L1 therapeutic antibodies\n* Treatment with systemic immunosuppressive medications\n* Cardiopulmonary dysfunction\n* Clinically significant history of liver disease, including cirrhosis, autoimmune hepatic disorders, HIV infection, or active Hepatitis B or Hepatitis C\n* Subject is pregnant or nursing\n* Known hypersensitivity to the components of the study drugs(s)",
    "sex": "ALL",
    "minimumAge": "18 Years",
    "stdAges": "ADULT, OLDER_ADULT"
}